Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy

Shi, Meixin; Ren, Yuqing; Xu, Hui; Weng, Siyuan; Ning, Wenjing; Ge, Xiaoyong; Liu, Long; Guo, Chunguang; Duo, Mengjie; Li, Lifeng; Li, Jing; Han, Xinwei

doi:10.1186/s12943-023-01738-6

Cited by 36 publications

(20 citation statements)

References 192 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its main principle is to introduce a small‐guide RNA (sgRNA) that can complement the target DNA sequence in the target cells so that it can bind to the Cas9 protein to form a complex. The complex can recognize, bind, and cleave the target DNA, allowing for gene editing 21,22 . Therefore, as described in the methods section, we transfected sgRNA and Cas9 expression vectors into cells simultaneously and obtained PANC‐1 cells with stable Pi16 knockout (Supporting Information: Figure ).…”

Section: Resultsmentioning

confidence: 99%

“…The complex can recognize, bind, and cleave the target DNA, allowing for gene editing. 21,22 Therefore, as described in the methods section, we transfected sgRNA and Cas9 expression vectors into cells simultaneously and obtained PANC-1 cells with stable Pi16 knockout (Supporting Information: Figure S3A). The genomes of PANC-1-Pi16 −/− and PANC-1 cells were amplified by PCR and then subjected to gel electrophoresis (Supporting Information:…”

Section: Upregulation Of Pi16 Is Associated With Poor Outcomes In Pda...mentioning

confidence: 99%

See 1 more Smart Citation

Peptidase inhibitor 16 promotes proliferation of pancreatic ductal adenocarcinoma cells through OASL signaling

Chen,

Jiang,

Cao

et al. 2024

Molecular Carcinogenesis

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is a highly invasive cancer with a poor prognosis and a 5‐year survival rate of less than 11%. As a member of the CAP superfamily of proteins, the role of peptidase inhibitor 16 (Pi16) in tumor progression is still unclear. Immunohistochemistry and quantitative RT‐PCR methods were used to detect the expression levels of Pi16 protein and mRNA in PDAC patients. CRISPR/Cas9 technology was used to knock out the expression of Pi16 in PDAC cell lines. In vivo and in vitro experiments were used to verify the effect of Pi16 on PDAC proliferation ability. By RNA sequencing, we found that oligoadenylate synthetase L (OASL) can serve as a potential downstream target of Pi16. The expression of Pi16 was higher in PDAC tissues than in matched adjacent tissues. High expression of Pi16 was associated with PDAC progression and poor prognosis. Overexpression of Pi16 could promote the proliferation of PDAC cells in vitro and in vivo. Bioinformatics analysis and coimmunoprecipitation assays showed that Pi16 could bind to OASL. Moreover, the functional recovery test confirmed that Pi16 could promote the proliferation of PDAC via OASL. Our present study demonstrates that Pi16 might participate in the occurrence and development of PDAC by regulating cell proliferation by binding to OASL, indicating that Pi16 might be a promising novel therapeutic target for PDAC.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Upregulation Of Pi16 Is Associated With Poor Outcomes In Pda...mentioning

confidence: 99%

Peptidase inhibitor 16 promotes proliferation of pancreatic ductal adenocarcinoma cells through OASL signaling

Chen,

Jiang,

Cao

et al. 2024

Molecular Carcinogenesis

View full text Add to dashboard Cite

show abstract

“…CRISPR/Cas9 system can regulate gene function, which activates or deactivates a gene. There are some immunosuppressive cells in TME, and we can knock out these suppressive molecules using CRISPR/Cas9 to achieve the purpose of treating cancer [95]. Recent advances and applications of CRISPR/Cas9 in cancer immunotherapy.…”

Section: Immunotherapy Combined Clustered Regularly Spaced Short Pali...mentioning

confidence: 99%

Nano-immunotherapy for lung cancer

Lu¹,

Zeng²,

Zhang³

et al. 2023

Nano TransMed

View full text Add to dashboard Cite

Lung cancer has the highest incidence and mortality rate worldwide. Immunotherapy is a universal treatment for lung cancer, but its overall treatment remains a challenge. Tumor immunoediting is a process in which the immune system restricts or promotes tumor development through elimination, equilibrium, and escape to change tumor immunogenicity and obtain an immunosuppressive mechanism to promote disease progression. An increasing number of immunotherapy drugs, including monoclonal antibody-targeting drugs and chimeric antigen (Ag) receptor-modified T cells (CAR-T cells), have been used in clinical therapy. Additionally, cancer vaccine development and new clustered regularly spaced short palindromes (CRISPR)based combination therapies against cancer open up new avenues for immunotherapy. However, these immunotherapies cause autoimmune induction and non-specific inflammation, with many limitations. The development and study of nanoparticle systems have shown the possibility of localization, pharmacokinetic programming, and immunomodulator co-delivery. Rapid advances in nanotechnology over the past decade have provided a strategic impetus for cancer immunotherapy improvements. Nanotechnology advancements in various aspects, such as virus-like size, high surface-volume ratio, and surface modifications to precisely target specific cell types, can be investigated through cancer vaccine and immunomodulator delivery system development. This review presents the current immunotherapy approaches for lung cancer and emphasizes the current process and prospects of the fusion of cancer immunotherapy, nanotechnology, bioengineering, and drug delivery.

show abstract

“…Drug and immunotherapy resistance is a big problem in long-term treatment, predominantly in oncology. CRISPR/Cas system can also be utilized to identify genes and mutations responsible for drug resistance and thereby help with individualized, effective therapy [ 157 ].…”

Section: Fundamentals Of the Future Crispr/cas9-based Therapymentioning

confidence: 99%

Multi-faceted CRISPR/Cas technological innovation aspects in the framework of 3P medicine

et al. 2023

View full text Add to dashboard Cite

Since 2009, the European Association for Predictive, Preventive and Personalised Medicine (EPMA, Brussels) promotes the paradigm change from reactive approach to predictive, preventive, and personalized medicine (PPPM/3PM) to protect individuals in sub-optimal health conditions from the health-to-disease transition, to increase life-quality of the affected patient cohorts improving, therefore, ethical standards and cost-efficacy of healthcare to great benefits of the society at large. The gene-editing technology utilizing CRISPR/Cas gene-editing approach has demonstrated its enormous value as a powerful tool in a broad spectrum of bio/medical research areas. Further, CRISPR/Cas gene-editing system is considered applicable to primary and secondary healthcare, in order to prevent disease spread and to treat clinically manifested disorders, involving diagnostics of SARS-Cov-2 infection and experimental treatment of COVID-19. Although the principle of the proposed gene editing is simple and elegant, there are a lot of technological challenges and ethical considerations to be solved prior to its broadly scaled clinical implementation. This article highlights technological innovation beyond the state of the art, exemplifies current achievements, discusses unsolved technological and ethical problems, and provides clinically relevant outlook in the framework of 3PM.

show abstract

Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy

Cited by 36 publications

References 192 publications

Peptidase inhibitor 16 promotes proliferation of pancreatic ductal adenocarcinoma cells through OASL signaling

Peptidase inhibitor 16 promotes proliferation of pancreatic ductal adenocarcinoma cells through OASL signaling

Nano-immunotherapy for lung cancer

Multi-faceted CRISPR/Cas technological innovation aspects in the framework of 3P medicine

Contact Info

Product

Resources

About